Jeong-woo Cho (SK Biopharmaceuticals)

SK Bio­phar­ma­ceu­ti­cals emerges from pan­dem­ic with pitch for $822M IPO

The live­ly biotech IPO streak isn’t con­fined in the US — or even Hong Kong for that mat­ter.

On Mon­day, SK Bio­phar­ma­ceu­ti­cals re­vealed that it’s eye­ing $822 mil­lion in what would be the coun­try’s biggest pub­lic de­but in three years.

Plans for the IPO be­gan as ear­ly as last Oc­to­ber, when SK filed a pre­lim­i­nary ap­pli­ca­tion to the Ko­re­an Ex­change. Ex­pec­ta­tions were high, with an­a­lysts pre­dict­ing that it could fetch up­wards of 1 tril­lion won (close to $850 mil­lion).

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.